# Pancreas cell type-specific regulatory variants and T2D disease risk association

> **NIH NIH F31** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2022 · $39,747

## Abstract

PROJECT SUMMARY
Type 2 diabetes (T2D) is a highly complex and heterogenous disease, affecting more than 400 million individuals
worldwide. While genome-wide association studies (GWAS) have identified more than 500 genomic loci that are
associated with T2D, most of these associations fail to delineate the causal genes and explain the molecular
mechanisms underlying disease pathology. To identify the causal genes, it is possible to exploit expression
quantitative trait locus (eQTL) analyses that have assessed the associations between genetic variation and gene
expression in the pancreas. Previous eQTL analyses of pancreatic islets have provided valuable insight into the
probable causal genes that contribute to T2D risk and disease, however they have not examined whether these
genes and their variant effectors are cell type-associated. Furthermore, the extent to which genetic variation
affects isoform expression is largely unknown despite an increasing importance of alternative splicing in
regulating beta cell function and survival. Advanced computational methods have been developed to accurately
resolve cell type populations within bulk heterogenous samples, allowing us to the map the associations between
genotype, cell type proportions, and gene expression. In Aim 1 of this proposal, I will perform cellular
deconvolution to estimate the proportions of pancreatic cell types in bulk RNA-seq of 305 whole pancreas and
420 pancreatic islets (725 samples in total) and use these estimations to generate a focused cell-type associated
eQTL map. In Aim 2, I will perform Bayesian colocalization between cell type-associated eQTLs and GWAS loci
to infer cellular mechanisms affecting T2D traits and disease. To identify putative causal regulatory variants
within the associated GWAS loci, I will conduct a fine-mapping study that integrates GWAS summary statistics
with functional annotations from epigenomic data and transcription factor (TF) binding activities from SELEX-
seq. In Aim 3, I will functionally validate the fine-mapped variants by testing whether or not they alter transcription
factor footprints in distinct pancreatic cell types using snATAC-seq. Next, using computational predictions from
this analysis and from Aims 1 and 2, I will prioritize 10 putative causal regulatory variants to interrogate their
direct effects on nuclear factor binding using electrophoretic mobility shift assay. Altogether, this proposal will
employ advanced computational methods to identify T2D risk variants that alter gene or isoform expression and
TF binding and determine the specific pancreatic cell types in which they are functional. These results will provide
novel insights into the genetic basis and cellular origins of T2D risk and disease.

## Key facts

- **NIH application ID:** 10536699
- **Project number:** 1F31DK131867-01A1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** Jennifer Phuong Nguyen
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $39,747
- **Award type:** 1
- **Project period:** 2022-09-15 → 2024-09-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10536699

## Citation

> US National Institutes of Health, RePORTER application 10536699, Pancreas cell type-specific regulatory variants and T2D disease risk association (1F31DK131867-01A1). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10536699. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
